GO:0030338 CMP-N-acetylneuraminate monooxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030338 describes the enzymatic conversion of CMP-N-acetylneuraminate to CMP-N-glycoloylneuraminate, a hydroxylation reaction requiring cytochrome b5 and molecular oxygen [4,6].
• The enzyme is encoded by CMAH (cytidine monophosphate-N-acetylneuraminic acid hydroxylase) in most mammals, but the gene is inactivated in humans, leading to absence of N-glycolylneuraminic acid (Neu5Gc).
• CMAH activity is essential for the biosynthesis of Neu5Gc, a sialic acid implicated in xenotransplantation rejection, cancer, and immune responses [1,5].
• The reaction uses a di-iron center and cytochrome b5 as an electron donor, and is localized to the cytosol.
• Loss of CMAH in humans may have evolutionary consequences, including altered sialic acid biology linked to metabolic and neurodegenerative diseases.
• Studying GO:0030338 requires molecular tools such as CRISPR knockout, point mutation, and overexpression models to dissect its role in health and disease.
Description
CMP-N-acetylneuraminate monooxygenase activity (GO:0030338) is a molecular function that catalyzes the hydroxylation of CMP-N-acetylneuraminate to form CMP-N-glycoloylneuraminate, a key step in the biosynthesis of the sialic acid N-glycolylneuraminic acid (Neu5Gc). This enzymatic activity is mediated by the CMAH gene product, which introduces a hydroxyl group into the N-acetyl moiety of sialic acids, converting Neu5Ac to Neu5Gc [4,6]. The reaction requires cytochrome b5 as an electron donor and molecular oxygen, and it occurs in the cytosol of mammalian cells. The presence of Neu5Gc on cell surfaces influences cell-cell interactions, immune recognition, and pathogen binding, making this activity a focal point in glycobiology, xenotransplantation, and cancer research [1,5]. In humans, the CMAH gene is inactivated, resulting in the absence of Neu5Gc and the accumulation of Neu5Ac. This evolutionary loss has profound implications for human physiology and disease susceptibility, including altered immune responses and potential links to metabolic disorders. Understanding GO:0030338 is therefore critical for researchers studying sialic acid biology, host-pathogen interactions, and the development of therapeutic strategies that target Neu5Gc-related pathways.
CMP-N-acetylneuraminate monooxygenase activity At A Glance
| GO ID | GO:0030338 |
|---|---|
| GO term | CMP-N-acetylneuraminate monooxygenase activity |
| Ontology | molecular_function |
| Synonym | CMP-N-acetylneuraminate hydroxylase activity; CMP-N-acetylneuraminic acid hydroxylase activity; CMP-Neu5Ac hydroxylase activity; cytidine monophosphoacetylneuraminate monooxygenase activity |
| Major function | Catalyzes the hydroxylation of CMP-N-acetylneuraminate to CMP-N-glycoloylneuraminate, a key step in Neu5Gc biosynthesis |
| Cofactors | Cytochrome b5, Fe(II), molecular oxygen |
| Subcellular location | Cytosol |
| Reaction direction | Forward: CMP-N-acetylneuraminate + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 → CMP-N-glycoloylneuraminate + 2 Fe(III)-[cytochrome b5] + H2O |
| Associated gene | CMAH (cytidine monophosphate-N-acetylneuraminic acid hydroxylase) |
What Is GO:0030338?
CMP-N-acetylneuraminate monooxygenase activity (GO:0030338) is defined as the catalysis of the reaction: CMP-N-acetyl-beta-neuraminate + 2 Fe(II)-[cytochrome b5] + 2 H+ + O2 = CMP-N-glycoloyl-beta-neuraminate + 2 Fe(III)-[cytochrome b5] + H2O. In simpler terms, this enzyme adds an oxygen atom to the N-acetyl group of CMP-N-acetylneuraminate, converting it to CMP-N-glycoloylneuraminate, using cytochrome b5 as an electron carrier and molecular oxygen as a substrate [4,6]. This activity is synonymous with CMP-N-acetylneuraminate hydroxylase activity and is essential for the production of N-glycolylneuraminic acid (Neu5Gc) in mammals.
Why Is CMP-N-acetylneuraminate monooxygenase activity Important in Cell Biology?
CMP-N-acetylneuraminate monooxygenase activity is critical for the biosynthesis of N-glycolylneuraminic acid (Neu5Gc), a sialic acid that plays diverse roles in cell recognition, immune modulation, and host-pathogen interactions [4,5]. In species that express the CMAH enzyme, Neu5Gc is a common cell surface component, but humans lack this activity due to a mutation in the CMAH gene, resulting in the absence of Neu5Gc and the presence of anti-Neu5Gc antibodies. This difference is a major barrier in xenotransplantation, where Neu5Gc on donor organs triggers hyperacute rejection. Moreover, Neu5Gc can be incorporated into human tissues from dietary sources and is associated with chronic inflammation and cancer progression. The evolutionary loss of CMAH in humans may also influence susceptibility to certain infections and metabolic diseases. Therefore, understanding the regulation and function of GO:0030338 is essential for advancing glycobiology, transplantation medicine, and cancer research.
• Neu5Gc biosynthesis: The enzyme is the sole source of Neu5Gc in mammals, a sialic acid with immunomodulatory properties.
• Xenotransplantation: Pig organs express Neu5Gc, which causes human antibody-mediated rejection; knockout of CMAH is a strategy to overcome this.
• Cancer biology: Neu5Gc accumulation in human tumors is associated with inflammation and tumor progression.
• Evolutionary biology: The inactivation of CMAH in humans may have provided protection against certain pathogens but increased risk for others.
• Immune response: Anti-Neu5Gc antibodies in humans can modulate immune reactions to biotherapeutics and dietary components.
• Metabolic disorders: Altered sialic acid metabolism linked to CMAH loss may contribute to conditions such as diabetes and cardiovascular disease.
• Neurodegeneration: Sialic acid changes have been implicated in amyotrophic lateral sclerosis and other neurodegenerative diseases.
• Biotechnology: CHO cells used for biopharmaceutical production can be engineered to reduce CMAH activity to avoid Neu5Gc incorporation.
• Glycoengineering: Modulating GO:0030338 enables control over sialic acid profiles for therapeutic glycoproteins.
• Research tool: CMAH knockout and transgenic models are valuable for studying sialic acid biology in vivo [1,8].
What Happens During CMP-N-acetylneuraminate monooxygenase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs its target molecule, CMP-N-acetylneuraminate, and prepares it for modification.
The enzyme CMP-N-acetylneuraminate monooxygenase (CMAH) specifically binds its substrate, CMP-N-acetylneuraminate, in the cytosol. This binding is a prerequisite for the subsequent hydroxylation reaction. The enzyme's active site accommodates the CMP-sialic acid moiety, positioning the N-acetyl group for attack by an oxygen species.
Electron transfer from cytochrome b5
In simple terms: A helper protein, cytochrome b5, supplies electrons that are needed to activate oxygen.
The hydroxylation reaction requires reducing equivalents, which are provided by cytochrome b5. In a reconstituted system, soluble cytochrome b5 purified from horse erythrocytes was shown to support CMP-N-acetylneuraminic acid hydroxylation activity in mouse liver cytosol. Cytochrome b5 donates electrons to the di-iron center of the enzyme, enabling the activation of molecular oxygen.
Oxygen activation and hydroxylation
In simple terms: Oxygen is split, and one of its atoms is inserted into the substrate to create Neu5Gc.
The enzyme utilizes a di-iron center to activate molecular oxygen, leading to the insertion of a hydroxyl group into the N-acetyl moiety of CMP-N-acetylneuraminate. This converts the substrate to CMP-N-glycoloylneuraminate, the immediate precursor of Neu5Gc. The reaction consumes two Fe(II) ions, two protons, and one oxygen molecule, producing water and two Fe(III) ions.
Product release and downstream utilization
In simple terms: The newly formed CMP-N-glycoloylneuraminate is released and used to build glycoconjugates.
After catalysis, CMP-N-glycoloylneuraminate is released from the enzyme and serves as a substrate for sialyltransferases in the Golgi apparatus, where it is incorporated into glycoproteins and glycolipids. This step is essential for the display of Neu5Gc on the cell surface, influencing cell-cell recognition and immune interactions.
Key Genes Involved in GO:0030338 CMP-N-acetylneuraminate monooxygenase activity
The following genes and proteins are directly or indirectly involved in CMP-N-acetylneuraminate monooxygenase activity and its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CMAH | Encodes the enzyme responsible for CMP-N-acetylneuraminate monooxygenase activity | Central to Neu5Gc biosynthesis; inactivated in humans; target for xenotransplantation and cancer studies [1,8] |
| CYB5A | Cytochrome b5, provides electrons for the hydroxylation reaction | Essential cofactor for CMAH activity; reconstitution studies demonstrate its role |
| CYB5B | Cytochrome b5 type B, may also support electron transfer | Potential alternative electron donor in some tissues |
| GNE | UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase, involved in sialic acid biosynthesis | Upstream of CMP-N-acetylneuraminate production; affects substrate availability |
| NANS | N-acetylneuraminate synthase, produces Neu5Ac | Provides the precursor for CMP-N-acetylneuraminate |
| CMAS | CMP-N-acetylneuraminate synthetase, activates Neu5Ac to CMP-Neu5Ac | Directly supplies the substrate for CMAH |
| SLC35A1 | CMP-sialic acid transporter | Transports CMP-sialic acids into the Golgi; affects downstream sialylation |
| ST3GAL1 | Sialyltransferase, adds sialic acid to glycans | Utilizes CMP-Neu5Gc for cell surface display |
| ST6GAL1 | Sialyltransferase, adds sialic acid in alpha-2,6 linkage | Competes with ST3GAL1 for CMP-sialic acid substrates |
| GGTA1 | Alpha-1,3-galactosyltransferase, produces Gal antigen | Co-targeted with CMAH in xenotransplantation to reduce immunogenicity |
| B4GALNT2 | Beta-1,4-N-acetyl-galactosaminyltransferase 2, produces Sda antigen | Another glycan antigen targeted in xenotransplantation |
| CD46 | Complement regulatory protein | Human transgene used to protect against complement in xenotransplantation |
| CD55 | Complement regulatory protein | Human transgene used in multi-edited pig donors |
| CD59 | Complement regulatory protein | Human transgene used in multi-edited pig donors |
| hTBM | Human thrombomodulin | Transgene to prevent coagulation in xenotransplantation |
| hCD39 | Human ectonucleoside triphosphate diphosphohydrolase 1 | Transgene to modulate inflammation in xenotransplantation |
| NEU1 | Sialidase, removes sialic acid from glycoconjugates | Counteracts sialylation; affects Neu5Gc turnover |
| NEU3 | Sialidase, acts on gangliosides | Modulates cell surface sialic acid and signaling |
How Is CMP-N-acetylneuraminate monooxygenase activity Regulated?
The activity of CMP-N-acetylneuraminate monooxygenase is primarily regulated at the level of CMAH gene expression and substrate availability. In humans, the CMAH gene is inactivated by a frameshift mutation, resulting in complete loss of enzyme activity. In other mammals, CMAH expression can be modulated by dietary factors and metabolic state, although specific transcriptional regulators are not fully defined. The enzyme requires cytochrome b5 and Fe(II) for activity, so availability of these cofactors can influence reaction rates. Additionally, the concentration of the substrate CMP-N-acetylneuraminate, which depends on upstream sialic acid biosynthesis enzymes such as GNE, NANS, and CMAS, can affect flux through this pathway. In engineered CHO cells, antisense RNA targeting CMAH reduced enzyme activity, demonstrating that expression levels directly correlate with activity.
CMP-N-acetylneuraminate monooxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CMAH | Xenotransplantation rejection; Neu5Gc antigenicity | CMAH knockout pig models; humanized mouse models |
| CMAH | Cancer; chronic inflammation from dietary Neu5Gc | CMAH-humanized mice; tumor xenografts with Neu5Gc exposure |
| CMAH | Evolutionary loss and metabolic disorders | CMAH knockout mice; comparative genomics [7,8] |
| GGTA1 | Hyperacute rejection in xenotransplantation | GGTA1/CMAH double knockout pigs |
| B4GALNT2 | Sda antigen-mediated rejection | B4GALNT2/CMAH knockout pigs |
Xenotransplantation rejection
The presence of Neu5Gc on pig endothelial cells is a major trigger of human antibody-mediated rejection in xenotransplantation. Humans lack CMAH activity and produce anti-Neu5Gc antibodies, which bind to pig organs and initiate complement activation [1,5]. To overcome this, pigs have been genetically engineered with CMAH knockout, often in combination with other glycan antigen knockouts such as GGTA1 and B4GALNT2, and with human complement regulatory transgenes (CD46, CD55, CD59) and coagulation-modulating genes (hTBM, hCD39). These multi-edited pigs show reduced human antibody binding and improved graft survival in preclinical models.
Cancer and chronic inflammation
Neu5Gc, the product of CMAH activity, can be incorporated into human tissues from dietary sources, particularly red meat and dairy. This foreign sialic acid is immunogenic and can induce chronic inflammation, which is associated with cancer progression. Anti-Neu5Gc antibodies may promote tumor growth by modulating immune responses. Additionally, Neu5Gc accumulation in tumors has been observed, and it can affect cell signaling and metastasis. Therefore, CMAH activity and Neu5Gc metabolism are potential targets for cancer immunotherapy and dietary interventions.
Evolutionary and metabolic implications
The inactivation of CMAH in humans is a unique evolutionary event that occurred after the divergence from chimpanzees. This loss may have provided protection against certain pathogens that use Neu5Gc as a receptor, but it also led to the accumulation of Neu5Ac and the production of anti-Neu5Gc antibodies [7,8]. Recent hypotheses suggest that this evolutionary change may have metabolic consequences, potentially contributing to susceptibility to diseases such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. However, direct causal links remain under investigation.
From CMP-N-acetylneuraminate monooxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of CMAH loss on Neu5Gc levels? | CMAH knockout cell lines (e.g., HEK293, CHO) [3,8] |
| How does CMAH point mutation affect enzyme activity? | Point mutation knock-in of catalytic residues in CMAH |
| Can CMAH overexpression increase Neu5Gc production? | CMAH overexpression in mammalian cells |
| What is the role of CMAH in xenotransplantation? | Multi-gene edited pigs (GGTA1/CMAH/β4GalNT2 KO + human transgenes) |
| How does CMAH activity influence cancer cell behavior? | CMAH knockout or overexpression in cancer cell lines |
| What is the subcellular localization of CMAH? | Tagged knock-in of CMAH with fluorescent protein |
How to Study the CMP-N-acetylneuraminate monooxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HPLC/MS | CMP-N-glycoloylneuraminate production | Enzyme activity assays |
| CRISPR-Cas9 knockout | Loss of CMAH function | Cell and animal models [1,3] |
| Lectin staining | Cell surface Neu5Gc | Flow cytometry and imaging |
| RNA-seq | Transcriptional changes in sialic acid pathways | Global gene expression analysis |
| Western blot | CMAH protein levels | Validation of knockout or overexpression |
| Immunofluorescence | Subcellular localization of CMAH | Cellular imaging |
| Reconstitution assay | Enzymatic activity with purified components | In vitro mechanistic studies |
| Anti-Neu5Gc antibody ELISA | Humoral immune response to Neu5Gc | Xenotransplantation and cancer studies [1,5] |
Enzymatic activity assays
CMP-N-acetylneuraminate monooxygenase activity can be measured using radiolabeled or fluorescently labeled substrates, followed by separation and detection of the product CMP-N-glycoloylneuraminate by HPLC or mass spectrometry [4,6]. Reconstitution assays with purified cytochrome b5 and cytosol fractions have been used to demonstrate activity in vitro.
Genetic manipulation and knockout models
CRISPR-Cas9 knockout of CMAH in cell lines and animal models is a powerful approach to study the loss of function. For example, CMAH knockout in CHO cells reduces Neu5Gc production and alters sialylation profiles. In pigs, CMAH knockout combined with other gene edits has been achieved to reduce xenotransplantation rejection.
Glycan analysis
Mass spectrometry and lectin-based assays can detect Neu5Gc on cell surfaces or glycoproteins. These methods are used to quantify the impact of CMAH activity on sialic acid composition [4,5].
Transcriptomic and proteomic profiling
RNA-seq and proteomics can reveal changes in sialic acid metabolism pathways upon CMAH manipulation. Such studies help identify downstream effects on immune response and cell signaling.
How CRISPR Can Be Used to Study GO:0030338 CMP-N-acetylneuraminate monooxygenase activity
Knockout
CRISPR-Cas9 knockout of CMAH is used to eliminate CMP-N-acetylneuraminate monooxygenase activity, resulting in the absence of Neu5Gc. This is particularly valuable in xenotransplantation research, where CMAH knockout pigs are generated to reduce human antibody binding. In cell lines, CMAH knockout models help dissect the role of Neu5Gc in cell signaling and immune interactions.
Point Mutation
Point mutations can be introduced into the CMAH gene to study catalytic residues or regulatory sites. For example, mutations in the di-iron center can abolish enzymatic activity, providing insights into the reaction mechanism. Such models are useful for structure-function studies.
Knock-in
Knock-in of a tagged CMAH (e.g., GFP or FLAG) allows visualization and purification of the enzyme for localization and interaction studies. Additionally, humanized CMAH knock-in mice can be generated to study the consequences of expressing the human pseudogene or to model Neu5Gc metabolism.
Overexpression
Overexpression of CMAH in mammalian cells increases CMP-N-acetylneuraminate monooxygenase activity and Neu5Gc production. This is used to study the effects of elevated Neu5Gc on cell behavior and to produce Neu5Gc-containing glycoproteins for research or therapeutic purposes.
How EDITGENE Supports CMP-N-acetylneuraminate monooxygenase activity Research
Researchers studying CMP-N-acetylneuraminate monooxygenase activity-related genes often need to determine whether a candidate gene is causally involved in Neu5Gc biosynthesis, immune recognition, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for CMP-N-acetylneuraminate monooxygenase activity research.
Frequently Asked Questions About CMP-N-acetylneuraminate monooxygenase activity
What is CMP-N-acetylneuraminate monooxygenase activity?
It is the enzymatic activity (GO:0030338) that converts CMP-N-acetylneuraminate to CMP-N-glycoloylneuraminate, a key step in the biosynthesis of N-glycolylneuraminic acid (Neu5Gc).
What gene encodes CMP-N-acetylneuraminate monooxygenase?
The CMAH gene encodes the enzyme responsible for this activity in most mammals, but it is inactivated in humans.
Why is CMP-N-acetylneuraminate monooxygenase important in xenotransplantation?
Pig organs express Neu5Gc due to CMAH activity, which triggers human antibody-mediated rejection; knocking out CMAH is a strategy to overcome this.
What cofactors are required for CMP-N-acetylneuraminate monooxygenase activity?
The enzyme requires cytochrome b5, Fe(II), and molecular oxygen for catalysis.
How is CMP-N-acetylneuraminate monooxygenase activity measured?
It can be measured using HPLC or mass spectrometry to detect the product CMP-N-glycoloylneuraminate, often with radiolabeled substrates.
What is the role of Neu5Gc in cancer?
Neu5Gc, the product of CMAH activity, can be incorporated into human tissues from diet and is associated with chronic inflammation and tumor progression.
Is CMAH active in humans?
No, the CMAH gene is inactivated in humans, so CMP-N-acetylneuraminate monooxygenase activity is absent.
What model organisms are used to study CMAH?
Mice, pigs, and cell lines such as CHO and HEK293 are commonly used, with CRISPR knockout or overexpression [1,3].
What diseases are linked to CMAH loss?
Loss of CMAH in humans has been hypothesized to influence susceptibility to infections, metabolic disorders, and neurodegeneration.
How can CRISPR be used to study CMP-N-acetylneuraminate monooxygenase activity?
CRISPR can create knockout, point mutation, knock-in, or overexpression models to dissect the function of CMAH and its role in disease [1,3,6].
Conclusion
CMP-N-acetylneuraminate monooxygenase activity (GO:0030338) is a critical enzymatic function in sialic acid biology, responsible for the production of Neu5Gc in mammals. Its absence in humans has profound implications for xenotransplantation, cancer, and evolutionary medicine. Understanding the regulation and function of this activity requires advanced molecular tools, including CRISPR-based models. EDITGENE offers comprehensive services to support researchers in dissecting the roles of CMAH and related genes, from knockout to overexpression and library screening.
References
- 1. Wang J et al.. 2025. Production and Functional Verification of 8-Gene (GGTA1, CMAH, β4GalNT2, hCD46, hCD55, hCD59, hTBM, hCD39)-Edited Donor Pigs for Xenotransplantation.. Cell Prolif 58(9):e70028 PMID: 40190036
- 3. Chenu S et al.. 2003. Reduction of CMP-N-acetylneuraminic acid hydroxylase activity in engineered Chinese hamster ovary cells using an antisense-RNA strategy.. Biochim Biophys Acta 1622(2):133-44 PMID: 12880951
- 4. Shaw L et al.. 1988. The biosynthesis of N-glycoloylneuraminic acid occurs by hydroxylation of the CMP-glycoside of N-acetylneuraminic acid.. Biol Chem Hoppe Seyler 369(6):477-86 PMID: 3202954
- 5. Cooper DK. 2016. Modifying the sugar icing on the transplantation cake.. Glycobiology 26(6):571-81 PMID: 26935763
- 6. Kozutsumi Y et al.. 1991. Reconstitution of CMP-N-acetylneuraminic acid hydroxylation activity using a mouse liver cytosol fraction and soluble cytochrome b5 purified from horse erythrocytes.. J Biochem 110(3):429-35 PMID: 1769971
- 7. Spedding M. 2025. Does Amyotrophic Lateral Sclerosis (ALS) Have Metabolic Causes from Human Evolution?. Cells 14(21) PMID: 41227379
- 8. Irie A et al.. 1998. CMP-N-Acetylneuraminic acid hydroxylase is exclusively inactive in humans.. Biochem Biophys Res Commun 248(2):330-3 PMID: 9675135
